Fri, Aug 22, 2014, 5:38 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Ironwood Pharmaceuticals, Inc. Message Board

  • rrtzrealmd rrtzrealmd Jul 30, 2012 12:24 PM Flag

    You simply must be joking...

    ...107 million shares...200 million in cash...burning around 35-40 million a quarter...and it's ONLY drug candidate is linaclotide?...which -- IF approved -- will be used to treat pain associated with irritable bowel syndrome??...pardon me a second:

    HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW, HAW!!!!

    ...oh, man!...that was a good one!...I may have to go change my depends after that!!...hoo-boy!...

    ...I mean, even ignoring an increasing amount of data suggesting lubiprostone may confer additional benefits beyond managing pain in IBS:

    http://www.biomedcentral.com/1471-2210/12/3/

    ...IRWD has yet to provide a cost/benefit analysis showing linaclotide is in any way superior to lubiprostone...a pretty good analysis given current data is available here:

    http://online.wsj.com/public/resources/documents/MarisAnalyst1027.pdf

    ...besides, lubiprostone has already "demonstrated a complete lack of "harm" to IBS patients with constipation, as defined by the study":

    http://www.amjmed.com/article/S0002-9343(11)00792-3/abstract

    ..and while so far the same be said for linaclotide, knowing what you got plays a big role in deciding what you're going to use as well as what reimbursers are willing to pay:

    http://www.businesswire.com/news/home/20110411005320/en/Surveyed-PCPs-Significantly-Gastroenterologists-Amitiza-Alosetron-Xifaxan

    ...compare to SCMP whose current market cap is so 170 million dollars...it is already drawing royalties 40 million a year; looks to gain further revenue as amitiza is will likely gain approval for treating opioid induced constipation...it should also begin to generate revenue from rescula in the not too distant future..it has $2 in cash while trading around $4...

    ...IRWD, on the other hand has $2 a share while trading at $13...but who even cares about that since IRWD is your typical biotech black hole of "cash burn" and is likely to require a secondary before its ONE drug ever makes it to market because that ONE drug has yet to even win approval -- much less prove its superiority to what's already available!...

    ...put it all together and what does IRWD amount to?...just another Forest Lab FUBAR!...HAW, HAW, HAW!!!...

 
IRWD
12.17-0.31(-2.48%)Aug 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.